Insmed Incorporated Q4 2025 Earnings Call Summary

Management attributed the exceptional 2025 performance to the 'stunning' early launch of Brinsupri and accelerated global growth of ARIKAYCE, particularly in Japan and Europe. The Brinsupri launch is exceeding internal benchmarks, with $144.6 million in net revenue during its first full quarter, positioning it as potentially the best specialty respiratory launch in history. The strategic focus is on 'owning' the bronchiectasis and NTM categories, leveraging a similar call point among pulmonologists fo ...